Hot Promising Stocks For 2014

It's a tough call for investors.

With the clinical trial failure rate for Alzheimer's drugs an astounding 99.6%, �major drugmakers have seen one promising Alzheimer's treatment after another fail. The list include Bapineuzumab (Pfizer/Johnson & Johnson), Flurizan (Myriad Genetics), and Elan's vaccine--all once seen as promising approaches to treating the disease.

Still, those who have close family members with Alzheimer's, as I do, are acutely aware of the disease's devastation. A new slate of drugs is badly needed, but it won't happen unless drugmakers keep paying the tab for research.

Right now, there is no drug which can halt or even slow the progression of any form of dementia. That's a huge tragedy because Alzheimer's (and other forms of dementia) have been accurately described as a "global disaster waiting to happen." According to the World Health Organization, there are almost 8 �million new cases of dementia a year. This is a staggering growth rate, and is�the same size as the populations of Switzerland and Israel.

Top 5 Income Companies To Buy For 2015: Array BioPharma Inc.(ARRY)

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Its programs under development include ARRY-520, a kinesin spindle protein inhibitor in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in Phase 1 clinical trial for patients with myelodysplastic syndrome; ARRY-380, a HER2 inhibitor in Phase 1 clinical trial for breast cancer; ARRY-797, a p38 inhibitor in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist in Phase 1 clinical trial for allergic inflammation. The company?s partnered drugs in clinical development comprise Selumetinib and AZD8330 MEK inhibitors for cancer in Phase 2 trial; MEK162 and MEK300 MEK inhibitors for cancer in Phase 2 trial; Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR inhibitor in Phase 2 trial for solid tumors; and LY2603618, a ChK-1 inhibitor in Phase 2 trial for cancer. Its partnered drugs in clinical development also include AMG 151, a glucokinase activator in Phase 1b trial for Type 2 diabetes; GDC-0068, a AKT inhibitor in Phase 1b trial for cancer; VTX-2337, a toll-like receptor in Phase 1b trial for cancer; VTX-1463, a toll-like receptor in Phase 1b trial for allergy; ARRY-382, a cFMS inhibitor in Phase 1 trial for cancer; and ARRY-575 and GDC-0425, which are ChK-1 inhibitors in Phase 1 trial for cancer. The company has collaborations with Amgen, Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech, Inc.; Novartis International Pharmaceutical Ltd.; InterMune, Inc.; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.

Advisors' Opinion:

• [By Dan Carroll]

  Array's phase 2 study pays off big
  It's tough to find a stock anywhere on the market that had as good a week as Array BioPharma (NASDAQ: ARRY  ) . Shares of the biotech picked up nearly 17.8% on the week, part of a 63.5% gain year-to-date. The company's developmental drug to treat persistent allergic asthma, ARRY-502, hit the right marks in improving patient lung function in phase 2 trial results. Even better for investors, Array CEO said several other health companies have shown interest to help the company in development of ARRY-502.

Hot Promising Stocks For 2014: Prudential Bancorp Inc. of Pennsylvania(PBIP)

Prudential Bancorp, Inc. of Pennsylvania operates as the holding company for Prudential Savings Bank that provides various financial products and services in Pennsylvania. Its deposit products include interest-bearing and non-interest-bearing checking, money market, savings, and certificate of deposit accounts. The company?s loan portfolio comprises single-family residential mortgage loans, construction and land development loans, non-residential or commercial real estate mortgage loans, home equity loans and lines of credit, commercial business loans, and consumer loans. The company also provides securities and insurance products, as well as automated teller machine and online banking services. As of September 30, 2010, it operated a main office and six branch offices located in Philadelphia and Delaware Counties. The company was founded in 1886 and is headquartered in Philadelphia, Pennsylvania. Prudential Bancorp, Inc. of Pennsylvania is a subsidiary of Prudential Mutu al Holding Company.

Advisors' Opinion:

• [By Jim Royal]

  I really like to invest in bank demutualizations, and my Special Situations portfolio is back to buy another one: Prudential Bancorp (NASDAQ: PBIP  ) . In October, the bank completed its second-step conversion, making it a fully public institution, but it trades at just 73% of tangible book value. That's tremendously cheap for a profitable, albeit slightly, bank. So I'm stepping up to buy the stock.

Hot Promising Stocks For 2014: Euromedis Groupe SA (EMG)

Euromedis Groupe SA is a France-based company that specializes in the design, manufacture, distribution, rental and export of medical and surgical equipment and products, and services for medical home care for hospitals, clinics, retirement homes, physicians, pharmacies, and individuals. The Company's product portfolio include products, such as syringes and needles; surgical equipment, such as catheters, instrumentation and compresses; gloves; hygiene products, comprising disposable clothing, masks and paper towel products, and pharmaceutical equipment, offering cotton wool and thermometers. Euromedis Groupe SA exports its products to Europe and Africa. Advisors' Opinion:

• [By Inyoung Hwang]

  Man Group Plc (EMG) advanced 3.6 percent to 85.85 pence. The world�� largest publicly traded hedge-fund manager posted its first quarterly net inflows in two years as clients added money to funds at its GLG Partners unit. Sales of Man Group�� funds totaled $4.1 billion in the third quarter, exceeding $3.4 billion of redemptions.

• [By Sofia Horta e Costa]

  Man Group Plc (EMG) jumped 6.8 percent to 104.3 pence. The world�� largest publicly traded hedge-fund manager said it no longer needs to hold a $300 million capital buffer after it confirmed with the U.K.�� Financial Conduct Authority a change in the company�� regulatory status.

• [By Sofia Horta e Costa]

  Commodity producers increased as base metals rallied, with BHP Billiton Ltd. (BHP), the largest mining company, climbing 3.7 percent. Man Group (EMG) Plc soared 13 percent on a plan to redeem debt. Royal Bank of Scotland Group Plc dropped by the most in two months after Britain�� biggest state-owned lender reported operating profit that fell short of analysts��estimates.

Hot Promising Stocks For 2014: Konica Minolta Inc (KNCAY)

Konica Minolta Holdings Inc. is a Japanese manufacturer. The Company's operating segments include Business Technologies, engaged in the manufacture of copy machines and printers; Optics, engaged in the production of optical devices and electronic materials, Photo Imaging, manufacturing photographic film and materials, ink-jet products and cameras, Medical and Graphic Imaging, engaged in the production of x-ray or graphic film and equipment for medical or graphic use, and Sensing, engaged in the manufacture of industrial or medical measurement instruments. The Others segment is engaged in the provision of business support services, the warehouse and delivery businesses, the management of real estate, the construction of facilities, the development of systems and the manufacture, sale and installation of planetariums, among others.

In March 2006, a portion of the camera production assets related to the development, design and production of digital single lens reflex (SLR) cameras was transferred to Sony Corporation. As a result, the Company ceased camera-related operations at the end of March 2006. In addition, minilab business activities were also discontinued in March 2006.

The Company competes with Canon, Xerox, Ricoh and HP.

Advisors' Opinion:

• [By Victor Selva]

  As we can see, the firm has a higher ROE than it peers: Ricoh Ltd. (RICOY), Konica Minolta Inc. (KNCAY), Canon�Inc. (CAJ); but is lower than the one registered by Pitney Bowes (PBI).